How can a patient and clinician respond to a GLP-1 denial under Medicare?

Respond to a GLP-1 denial from Medicare by filing a formal appeal with a letter of medical necessity or exploring non-covered, physician-supervised options.

Understanding Medicare's Stance on Weight Loss Medications

Medicare Part D plans are legally prohibited by the Social Security Act from covering medications used for anorexia, weight loss, or weight gain. This statutory exclusion is the primary reason for denials when a GLP-1 medication like Wegovy or Zepbound is prescribed solely for chronic weight management.

However, Part D plans are required to cover GLP-1 medications when prescribed for a 'medically accepted indication.' This includes type 2 diabetes (T2D) for drugs like Ozempic, Rybelsus, Mounjaro, and Trulicity. Coverage is determined by the FDA-approved use of the specific drug.

A recent clarification from the Centers for Medicare & Medicaid Services (CMS) in 2024 has created an important nuance. If a drug gains an additional FDA approval for a medically accepted indication beyond weight loss, Part D plans can cover it for that specific use.

For example, Wegovy (semaglutide) is now FDA-approved to reduce the risk of major adverse cardiovascular events (like heart attack and stroke) in adults with established cardiovascular disease and either obesity or overweight. For patients who meet these specific criteria, Part D plans can cover Wegovy for this risk-reduction use, even though it also causes weight loss.

Navigating the Medicare Part D Appeals Process

If a GLP-1 is denied, the patient and clinician can initiate a formal, five-level appeals process. The first level is a 'Redetermination' request submitted directly to the Medicare drug plan. This is the most common and critical step in challenging a denial.

The clinician should submit a 'Request for Redetermination' form or a formal letter of medical necessity. This document must clearly articulate why the medication is being prescribed for a covered indication, such as T2D or cardiovascular risk reduction, not just for weight management.

A strong letter of medical necessity includes the patient's diagnosis, relevant comorbidities (e.g., A1c levels, history of heart attack), a list of previously failed medications, and a clinical justification for why the specific prescribed GLP-1 is medically necessary over other formulary alternatives.

If the initial redetermination is denied, subsequent appeal levels include: Reconsideration by an Independent Review Entity (IRE), a hearing with an Administrative Law Judge (ALJ), a review by the Medicare Appeals Council, and finally, a judicial review in federal court.

Requesting a Formulary or Tiering Exception

In some cases, a denial occurs because the specific GLP-1 is not on the plan's list of covered drugs (its formulary), even if the patient has a covered diagnosis like T2D. Here, a 'formulary exception' can be requested.

A formulary exception request requires the prescribing clinician to provide a statement explaining why formulary drugs are not suitable for the patient. This could be due to contraindications, a history of adverse effects, or a lack of efficacy from other covered medications.

Another option is a 'tiering exception.' If the GLP-1 is on the formulary but in a high-cost tier with a prohibitive copay, an exception can be requested to have it covered at a lower-cost tier. This can make a covered medication more affordable.

Both exception types require strong supporting documentation from the physician. The success of an exception request hinges on demonstrating that the prescribed drug is a medical necessity and that alternatives are clinically inappropriate for that specific patient.

Alternative Access and Payment Options

If appeals are unsuccessful because the prescription is for weight loss only, other avenues exist. Many pharmaceutical manufacturers, including Novo Nordisk and Eli Lilly, operate Patient Assistance Programs (PAPs) that provide medications at low or no cost to eligible individuals.

PAPs typically have strict income thresholds and require the patient to have no prescription drug coverage for the medication in question. A formal denial from Medicare Part D may help a patient qualify for a manufacturer's PAP.

For patients who are denied coverage and do not qualify for a PAP, a physician-supervised medical weight loss program may be an option. These programs, like the one offered by GOAL.MD, may utilize compounded medications prepared by licensed U.S. pharmacies. Compounded medications are not FDA-approved.

Finally, a clinician may discuss alternative, often older and more affordable, weight management medications. Drugs like phentermine, bupropion-naltrexone, or orlistat may be covered by some plans or have lower out-of-pocket costs, though they have different efficacy and side effect profiles than GLP-1 agonists.

Bottom Line

Medicare's statutory exclusion of weight loss drugs remains the largest barrier to GLP-1 coverage for obesity. Denials for this reason are common and based on federal law.

The most effective response to a denial is a formal appeal focused on a covered indication like type 2 diabetes or, for Wegovy, cardiovascular risk reduction in specific patients. This requires detailed clinical documentation from the physician.

If a prescription is solely for weight management without a co-occurring covered indication, a Medicare Part D appeal is unlikely to succeed. In this scenario, patients and clinicians should explore manufacturer Patient Assistance Programs, cash-pay options, or physician-supervised programs using compounded medications.

This article is for informational purposes only and does not constitute medical advice.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.